MAPS’ effort to start research at Harvard into

MAPS’ effort to start research at Harvard into the use of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced cancer began a new phase today, as Dr. John Halpern submitted a draft of the protocol to the McLean Hospital Institutional Review Board (IRB) for preliminary review. We anticipate several months of review and discussion before we will be able to determine if the protocol will be accepted. If so, the study then moves to the Lahey Clinic IRB for further review (Dr. Todd Shuster, oncologist co-investigator, works at Lahey Clinic and will refer subjects to participate in the study), and then on to the FDA. We’re hoping that this study will be the vehicle to restart psychedelic research at Harvard again, for the first time since 1965!